Roche Holding ahead of the Xetra open; Enicepatide phase II results reported

Roche Holding is ahead of the Xetra open with attention on Enicepatide. A September 22 report said the phase II study reached all primary objectives.

Roche Holding is ahead of the Xetra open as investors assess a reported development milestone for Enicepatide, the company’s investigational obesity and diabetes treatment. A finanzen.at report dated September 22, 2026, citing Roche, said the phase II clinical trial reached all primary study objectives.

Further development planned

Enicepatide has not been approved. Roche plans to continue developing the drug and to test it in a phase III study focused on blood-glucose control, according to the dated report. The company also has two phase III weight-loss studies in advanced stages. finanzen.at